VSN16R / Ipsen, University College London - LARVOL DELTA

Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium Channels. (PubMed, Pharmaceuticals (Basel)) - "Following the treatment with the BK channel openers, BMS-204253 and VSN16R, neuroprotection was assessed using subjective and objective clinical outcomes and by quantitating spinal nerve content...However, it inhibited the accumulation of nerve loss and disability as a consequence of autoimmunity. Therefore, in addition to symptom control, BK channel openers have the potential to save nerves from excitotoxic damage and could be useful as either stand-alone neuroprotective agents or as add-ons to current disease-modifying treatments that block relapsing MS but do not have any direct neuroprotective activity."

Journal • CNS Disorders • Immunology • Multiple Sclerosis

Reversal of behavioural phenotype by the cannabinoid-like compound VSN16R in fragile X syndrome mice. (PubMed, Brain) - "Moreover, VSN16R showed no evidence of tolerance, which strongly suggests that chronic VSN16R may have great therapeutic value for fragile X syndrome and autism spectrum disorder. This study provides new insight into the pathophysiology of fragile X syndrome and identifies a new pathway for drug intervention for this debilitating disorder."

Journal • Preclinical • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Fragile X Syndrome • Genetic Disorders • Mental Retardation • Multiple Sclerosis

Canbex Therapeutics announces the appointment of new chief medical officer (B3c Newswire) - "Canbex has successfully completed the Single Ascending Dose (SAD) stage of its Phase I study of VSN16R, with highly encouraging results.The Multiple Ascending Dose (MAD) part of the trial is due to start imminently."

Anticipated new P1 trial • Multiple Sclerosis

Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis (clinicaltrials.gov) - P2; N=160; Completed; Sponsor: Canbex Therapeutics Ltd; Recruiting ➔ Completed

Trial completion • Biosimilar • CNS Disorders • Multiple Sclerosis

The Cannabinoid-Like Compound, VSN16R, Acts on Large Conductance, Ca-Activated K Channels to Modulate Hippocampal CA1 Pyramidal Neuron Firing. (PubMed, Pharmaceuticals (Basel)) - "These findings demonstrate that VSN16R has effects in native hippocampal neurons consistent with its causing an increase in initial firing frequency via activation of IBTX-sensitive BK channels. The differential pharmacological effects described suggest that VSN16R may differentially target BK channel subtypes."

Journal